Gladius Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Gladius Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-8,150	Closed	-$5.86M	–	432
2023 Q2	$5.86M	Buy	8,150 +3,223	+65%	+$2.48M	0.29%	39
2023 Q1	$4.05M	Buy	+4,927	New	+$3.72M	0.24%	59
2022 Q3	–	Sell	-15	Closed	-$9K	–	482
2022 Q2	$9K	Buy	+15	New	+$9.75K	﹤0.01%	337
2022 Q1	–	Sell	-146	Closed	-$93K	–	330
2021 Q4	$93K	Buy	+146	New	+$89.8K	0.01%	259

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Gladius Capital Management's REGN Position: Q3 2023 in Review

Gladius Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2023, closing a stake of 8,150 shares — an estimated $5.86M sold.

Gladius Capital Management first reported a position in REGN in Q4 2021 and held it in 4 quarters. The position peaked at $5.86M in Q2 2023. 1,177 funds tracked by Wall St. Rank hold REGN as of Q3 2023.

Gladius Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Gladius Capital Management sold 8,150 Regeneron Pharmaceuticals shares in Q3 2023, an estimated $5.86M.
Gladius Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2021 and held it in 4 quarters.
Gladius Capital Management's Regeneron Pharmaceuticals position peaked at $5.86M in Q2 2023.
1,177 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2023.

Based on Gladius Capital Management's 13F filing for Q3 2023, filed 10 Oct 2023.